Innovative Cuban biotech drug • Passive immunotherapy against target overexpressed in epithelial tumors • Potentiates antitumor effect in combination with radiotherapy/chemotherapy • Prolong survival • Increase quality of live • Drug very safety as pediatric as adult patients
Commercial names CIMAher®, TheraCIM®, BIOMAb EGFR®, Theraloc®, Laedemab®
